Allarity Therapeutics, Inc. (ALLR)
NASDAQ: ALLR · Real-Time Price · USD
0.8033
-0.0329 (-3.93%)
At close: Jun 13, 2025, 4:00 PM
0.8200
+0.0167 (2.08%)
After-hours: Jun 13, 2025, 7:59 PM EDT
Allarity Therapeutics Employees
As of December 31, 2024, Allarity Therapeutics had 7 total employees, including 6 full-time and 1 part-time employees. The number of employees increased by 1 or 16.67% compared to the previous year.
Employees
7
Change (1Y)
1
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$3,429,429
Market Cap
12.11M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
ALLR News
- 3 days ago - Allarity Therapeutics Announces Changes to Board of Directors - GlobeNewsWire
- 5 weeks ago - Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment - GlobeNewsWire
- 2 months ago - ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - PRNewsWire
- 3 months ago - ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - PRNewsWire
- 3 months ago - Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission - GlobeNewsWire
- 3 months ago - Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration - GlobeNewsWire
- 3 months ago - Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients - GlobeNewsWire
- 4 months ago - Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Accesswire